RxDoctor Payments Data

Karen Bulaong, PA

Physician Assistant · Cherry Hill, NJNPI 1063110385

Payments from drug & device makers

$4,140in general payments, 2019–2025

Across 206 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$490
  • SK Life Science, Inc.$243
  • Axsome Therapeutics, Inc.$187
  • Jazz Pharmaceuticals Inc.$165
  • Neurelis, Inc.$161
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,140100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,140 in reported general payments places this provider in the 90th percentile of 2,726 physician assistant providers in New Jersey.

See all physician assistant providers in New Jersey

Medicare billing

Part B allowed, 2024
$64,697
Medicare patients
157
Services billed
6,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate59$71,247
UbrelvyUbrogepant50$68,606
BriviactBrivaracetam15$47,583
ValtocoDiazepam21$46,879
Nurtec OdtRimegepant Sulfate27$38,553
Emgality PenGalcanezumab-Gnlm25$22,750
Lacosamide126$20,321
FycompaPerampanel14$12,511
Aimovig AutoinjectorErenumab-Aooe12$8,896
Clobazam17$7,138
Levetiracetam97$5,754
Oxcarbazepine25$3,116
Diazepam16$2,737
Topiramate103$1,658
Atorvastatin Calcium109$1,397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$243$71,24759 claims
AbbVieUbrelvy$1,669$68,60650 claims
UCB, Inc.Briviact$490$47,58315 claims
Neurelis, Inc.Valtoco$161$46,87921 claims
PfizerNurtec Odt$112$38,55327 claims
Eisai Inc.Fycompa$29$12,51114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,726 physician assistant providers in New Jersey.

Other physician assistant in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →